Condition: Diffuse Large B-Cell Lymphoma · High-grade B-cell Lymphoma · Transformed Lymphoma · Sponsor: Jonsson Comprehensive Cancer Center
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.
This description comes directly from the study's public registry record.
Vlad Kustanovitch · 310-206-5756 · VKustanovich@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| University of Oklahoma | Oklahoma City, Oklahoma, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05256641